

Miosis prevention and post-op ocular pain reduction in one¹

OMIDRIA[®] (phenylephrine and ketorolac injection) 1% / 0.3%
IS COVERED FOR MORE CATARACT
SURGERY PATIENTS THAN YOU THINK



Introducing

OMIDRIAssure[™]

COVERAGE WITH CONFIDENCE

Now you can provide the benefits of
OMIDRIA—without worrying about
coverage and reimbursement

- EXPANDED COVERAGE FOR PATIENTS
- REIMBURSEMENT ASSISTANCE
FOR PHYSICIANS AND FACILITIES

INDICATIONS AND USAGE

OMIDRIA[®] is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

Systemic exposure of phenylephrine may cause elevations in blood pressure.

The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Use of OMIDRIA in children has not been established.

Please see additional Important Safety Information on back cover and the Full Prescribing Information at www.omidria.com/prescribinginformation.



OMIDRIA[®]

(phenylephrine and
ketorolac injection) 1% / 0.3%



CHOOSE OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3%
FOR YOUR NEXT PATIENT—
WITH CONFIDENCE THAT IT'S COVERED

OMIDRIAssure™
COVERAGE WITH CONFIDENCE

Easy access to comprehensive reimbursement services for all of your cataract procedures

LIVE ASSISTANCE
INFORMATION HOTLINE



Personalized help with reimbursement services related to OMIDRIA, including:

- General program inquiries
- Eligibility checks
- Benefits verifications
- Prior authorizations
- Start-to-finish assistance with coding and claims

For live assistance, call the OMIDRIAssure hotline at **1-877-OMIDRIA** (1-877-664-3742) 9 AM-6 PM ET, Monday-Friday

Quick turnaround times to help ensure coverage while staying on schedule with surgery

1 BUSINESS DAY

- Insurance coverage determinations
- Billing and coding questions
- General program inquiries

2 BUSINESS DAYS

- Benefits verifications
- Notifications of need for prior authorization

OMIDRIA is now covered for all of your cataract surgery patients

“WE PAY THE DIFFERENCE”
COMMERCIAL REIMBURSEMENT PROGRAM



Assistance for patients with insufficient commercial insurance

Omeros will pay your facility, on behalf of your patient, the difference between your facility's acquisition cost for OMIDRIA and the amount covered by your patient's insurance less a \$30 patient responsibility

“EQUAL ACCESS”
PATIENT ASSISTANCE PROGRAM



Assistance for financially eligible uninsured or government-insured patients

- Eligible patients will receive OMIDRIA at no cost
- Free vial will be sent to your facility prior to surgery



Start enrolling patients in OMIDRIAssure today!
Fax the completed, signed Patient Enrollment Form to **1-855-664-3741**

BECAUSE EVERY PATIENT DESERVES ACCESS TO OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3%...



Follow these 3 easy steps and leave the coverage and reimbursement worries to us

STEP 1

Enroll your patient in OMIDRIAssure prior to surgery*

OMIDRIAssure will provide your facility with patient-specific coverage and reimbursement information. If your uninsured or government-insured patient qualifies for the "Equal Access" Patient Assistance Program, you will receive a free vial for your patient's procedure.*

STEP 2

Deliver the benefits of OMIDRIA during your patient's cataract surgery

Use OMIDRIA in your cataract surgery patients regardless of coverage type. If your facility did not receive a free vial through the "Equal Access" Patient Assistance Program for your patient's surgery, bill for OMIDRIA using its unique HCPCS code (C9447) when submitting your reimbursement claim for the procedure.

STEP 3

If your patient's commercial coverage is insufficient, send the related EOB to OMIDRIAssure and Omeros pays the difference

If your patient's commercial insurance payment for OMIDRIA does not cover your facility's cost, submit the Explanation of Benefits (EOB) to OMIDRIAssure. Omeros will pay your facility, on behalf of your patient, the difference between your facility's acquisition cost for OMIDRIA and the insurance payment less a \$30 patient responsibility.



*To be eligible for either the "Equal Access" Patient Assistance Program or the "We Pay the Difference" Commercial Reimbursement Program, patients must be enrolled in OMIDRIAssure prior to surgery. For any patient for whom your facility received a free vial through the "Equal Access" Patient Assistance Program, the patient's insurance carrier(s) should not be billed for OMIDRIA.



Start enrolling patients in OMIDRIAssure™ today!

Fax the completed, signed Patient Enrollment Form to **1-855-664-3741**
(Request forms from your Omeros Representative or from the OMIDRIAssure Hotline)



For more information, call the OMIDRIAssure Hotline at **1-877-OMIDRIA**
(1-877-664-3742) 9 AM-6 PM ET, Monday-Friday

IMPORTANT SAFETY INFORMATION

OMIDRIA® must be added to irrigation solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure of phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-inflammatories (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Use of OMIDRIA in children has not been established.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS AND USAGE

OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.

Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2015.

OMEROS®, the Omeros logo®, OMIDRIA®, and the OMIDRIA logo® are registered trademarks, and OMIDRIAssure™ is a trademark, of Omeros Corporation.
© Omeros Corporation 2015, all rights reserved. 2015-212

